Holen Sie sich die Stockscreener-App
1.91
8.52%
0.15
Handel nachbörslich:
1.91
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CytomX's High-Risk, High-Reward ADC Strategy: Can CX-2051 Overcome Safety Hurdles and Deliver Value? - AInvest
Published on: 2025-08-15 21:04:24 - sundaytimes.kr
CytomX Therapeutics Soars 10.23% on Clinical Trial Progress - AInvest
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - MSN
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - MSN
Barclays sees ‘significant potential’ in CytomX’s CX-2051 despite safety event - MSN
Cancer patient dies in clinical trial, drugmaker's stock falls, but the study goes on - The Business Journals
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26% - simplywall.st
Slammed 26% CytomX Therapeutics, Inc. (NASDAQ:CTMX) Screens Well Here But There Might Be A Catch - 富途牛牛
CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com Australia
Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛
CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus
CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria
CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener
CytomX Therapeutics Provides Update On CX-2051 Phase 1 Study - TradingView
CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan
Published on: 2025-08-13 07:49:54 - sundaytimes.kr
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Inc. Inches Above Key Support — Safe to HoldMarket Momentum Signal Generator Shows Trends - beatles.ru
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
CytomX Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Posts Q2 2025 Financials, Announces Positive CX-2051 Results, and Extends Runway to Q2 2027. - AInvest
CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising - AInvest
CytomX Reports Q2 Revenue Drop of 26%, Narrows Operating Losses Amid Pipeline Progress - AInvest
CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool
CytomX (CTMX) Q2 Revenue Drops 26% - Nasdaq
CytomX Therapeutics reports Q2 EPS 0c, consensus (6c) - TipRanks
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - Yahoo Finance
CytomX Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
CytomX Therapeutics Announces Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc Q2 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $18.7 Million - GuruFocus
CytomX Therapeutics files $250M mixed securities shelf - AInvest
CytomX Therapeutics Q2 Revenue Beats Estimates, Earnings Up 23.5M - AInvest
CytomX Therapeutics beats Q2 revenue estimates - MarketScreener
CytomX Earnings: Breakthrough Colorectal Cancer Drug Shows Promise as Company Raises $100M - Stock Titan
CytomX Therapeutics to Report Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Oppenheimer Initiates Coverage on CytomX Therapeutics (NASDAQ:CTMX) - MarketBeat
What are the technical indicators suggesting about CytomX Therapeutics Inc.Explosive earning power - Jammu Links News
Is CytomX Therapeutics Inc. a good long term investmentGame-changing returns - Jammu Links News
How volatile is CytomX Therapeutics Inc. stock compared to the marketGame-changing capital returns - Jammu Links News
CytomX Therapeutics (NASDAQ:CTMX) shareholders have earned a 79% return over the last year - Yahoo Finance
Why is CytomX Therapeutics Inc. stock attracting strong analyst attentionCapitalize on market trends with confidence - Jammu Links News
What institutional investors are buying CytomX Therapeutics Inc. stockCapitalize on fast-moving trading opportunities - Jammu Links News
What is the risk reward ratio of investing in CytomX Therapeutics Inc. stockCapitalize on market trends before they peak - Jammu Links News
Does CytomX Therapeutics Inc. stock perform well during market downturnsFree Capital Growth Strategies - Jammu Links News
What are analysts’ price targets for CytomX Therapeutics Inc. in the next 12 monthsInvest smarter with data-backed trading alerts - Jammu Links News
What are the latest earnings results for CytomX Therapeutics Inc.Overwhelming financial success - Jammu Links News
What is CytomX Therapeutics Inc. company’s growth strategyRapid capital growth - Jammu Links News
What makes CytomX Therapeutics Inc. stock price move sharplyFree Trading Psychology Coaching - Jammu Links News
How strong is CytomX Therapeutics Inc. company’s balance sheetMaximize returns with effective portfolio management - Jammu Links News
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):